{'output': [['Boehringer Ingelheim', 'ORG', 'Announce', 'sNDA', 'ORG/REG'], ['Boehringer Ingelheim', 'ORG', 'Operate_In', 'Pharmaceuticals', 'SECTOR'], ['sNDA', 'ORG/REG', 'Relate_To', 'Gilotrif', 'PRODUCT'], ['Gilotrif', 'PRODUCT', 'Has', 'EGFR mutations', 'CONCEPT'], ['Gilotrif', 'PRODUCT', 'Has', 'non-resistant EGFR mutations', 'CONCEPT'], ['Gilotrif', 'PRODUCT', 'Has', 'L861Q mutation', 'CONCEPT'], ['Gilotrif', 'PRODUCT', 'Has', 'G719X mutation', 'CONCEPT'], ['Gilotrif', 'PRODUCT', 'Has', 'S768I mutation', 'CONCEPT'], ['Gilotrif', 'PRODUCT', 'Operate_In', 'NSCLC treatment', 'SECTOR'], ['Gilotrif', 'PRODUCT', 'Control', 'FDA approval', 'ORG/REG'], ['FDA', 'ORG/REG', 'Control', 'Gilotrif approval', 'PRODUCT'], ['FDA', 'ORG/REG', 'Control', 'sNDA evaluation', 'ORG/REG'], ['FDA', 'ORG/REG', 'Grant', 'Priority Review status', 'ORG/REG'], ['U.S.', 'GPE', 'Participates_In', 'Gilotrif approval', 'PRODUCT'], ['NSCLC', 'CONCEPT', 'Has', 'EGFR mutations', 'CONCEPT'], ['NSCLC', 'CONCEPT', 'Has', 'non-resistant EGFR mutations', 'CONCEPT'], ['NSCLC', 'CONCEPT', 'Has', 'L861Q mutation', 'CONCEPT'], ['NSCLC', 'CONCEPT', 'Has', 'G719X mutation', 'CONCEPT'], ['NSCLC', 'CONCEPT', 'Has', 'S768I mutation', 'CONCEPT'], ['LUX-Lung clinical trial program', 'EVENT', 'Relate_To', 'Gilotrif', 'PRODUCT'], ['Physician', 'PERSON', 'Conducts', 'biomarker testing', 'PRODUCT'], ['Patient', 'PERSON', 'Eligible_For', 'Gilotrif', 'PRODUCT'], ['Lung cancer', 'CONCEPT', 'Has', 'squamous cell carcinoma', 'CONCEPT'], ['Lung cancer', 'CONCEPT', 'Has', 'platinum-based chemotherapy', 'PRODUCT'], ['Child', 'PERSON', 'Not_Known_If_Safe_And_Effective', 'Gilotrif', 'PRODUCT']]}